MarketVIEW - Chlamydia trachomatis vaccines

  • June 2012
  • -
  • VacZine Analytics Group Of Assay Advantage Ltd

Chlamydia trachomatis (CT) is an intracellular Gram-negative bacterium and a leading cause worldwide of sexually-transmitted disease and preventable blindness. The pathogen is a major cause of serious reproductive complications in the female with outcomes such as pelvic inflammatory disease (PID) and ectopic pregnancies.

Although diagnosed infections with Chlamydia trachomatis are curable with antibiotic therapy the vast majority infections are "silent" and unrecognized. This is of concern due to continued transmission especially among individuals below 30 years of age. Prophylatic vaccines could prevent CT primary infection, reinfection or lessen the incidence and severity of PID, or similar long-term sequelae. A key question for vaccine manufacturers is whether a CT vaccine would be deployed alongside HPV vaccines in the preadolescent population, thus providing a sizeable commercial opportunity.

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for a putative CT vaccine until 2035. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on new adolescent vaccines.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

Table Of Contents

Contents - Summary presentation (MS PowerPoint based)

Executive Summary
Commercial model - key outputs
Total available demand: Chlamydia vaccine, global, (000s doses)
Total available demand: Chlamydia vaccine, high-income markets, (000s doses)
Total available demand: Chlamydia vaccine, emerging markets, (000s doses)
Total available market: Chlamydia vaccine, global, ($ 000s)
Total available market: Chlamydia vaccine, by market, ($ 000s)
Total available market: Chlamydia vaccine, price sensitivity analysis, ($ 000s)
Chlamydia vaccine: country volume analysis, 2025 (000s doses)
Chlamydia vaccine: country value analysis, 2025 ($ 000s)
The role of a CT vaccine
Commercial model - key assumptions
Pricing
Model forecast comparisons: June 2011 v current
Chlamydia vaccine opportunity: target product profile
Overall commercial model assumptions per country
Chlamydia trachomatis: brief background
Clinical features
Chlamydia trachomatis: natural history of infection
Chlamydia trachomatis: global incidence
Chlamydia trachomatis: global prevalence
US epidemiology
UK epidemiology
Reasons for increasing incidence
Potential impact of a CT vaccine
Competitor landscape: overview
Competitive environment: major players
Chlamydia trachomatis vaccine - HPV, a relevant case study?
HPV vaccines: analysis of country uptake
Bibliography
Disclaimer
About VacZine Analytics

PAGES: ~57 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents - Vaccine demand model (MS Excel-based)

Title Sheet
Scenario definition
Value Scenario Analysis
Value Summary (Western)
Volume Summary (Western)
Value Summary (Emerging)
Volume Summary (Emerging)
Charts - volume (Western)
Charts - value (Western)
Charts - value/volume (Western)
Females (Western)
US (13 yrs/ 14 - 18 yrs)
Canada
UK
France
Germany
Italy
Spain
Other EU
Australia
Japan
Females (Emerging)
Brazil
Russia
India
China
Mexico
Population database
Competition - IP landscape
Assumptions - major markets
Back page
About VacZine Analytics
Disclaimer

WORKSHEETS: ~65

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Antifungal Drugs : Technologies and Global Markets

Antifungal Drugs : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This report aims to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 through 2018. It covers approved human therapeutics ...

DNA Vaccines: Technologies and Global Markets

DNA Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2014
  • by BCC Research

This BCC Research study determines the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. High growth and market potential segments of the ...

Detailed I/E report of Carbendazim export analysis

Detailed I/E report of Carbendazim export analysis

  • $ 5 400
  • Industry report
  • July 2014
  • by CCM International Limited

Carbendazim export analysis will help clients indentify export situation of technical and formulations with exclusive research methods, to offer not only the target products' export volume, price, time, ...


1 Companies

Company Profiles

OPKO Health Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.